Mountain Valley MD Holdings Inc. announced that it has filed for an accelerated review of its macrocyclic lactone solubilization patent with the United States Patent and Trademark Office ("USPTO"). To support the accelerated patent examination request, the Company has provided the USPTO with new formulation analyses of different diluted concentrations of its QuicksolTM Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party CRO. The Company previously confirmed its ability to make the anti-parasitic drug Ivermectin highly water-soluble without the use of organic solvents, improving its water solubility by nearly 5,000 times and that it had completed its initial safety and improved efficacy in pre-clinical validation with a leading third-party preclinical contract research organization ("CRO"). The pre-clinical trials confirmed a significant improvement in the Ivermectin pharmacokinetics and efficacy when applied through its QuicksomeTM and QuicksolTM technologies versus existing oral and subcutaneous forms. MVMD's solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. The Company has been closely monitoring the global studies and reports that demonstrate the efficacy of the drug Ivermectin as a therapeutic for COVID-19, including the ongoing work from the Front Line COVID-19 Critical Care Alliance ("FLCCC Alliance") and its recent publication outlining the evidence base supporting the efficacy of Ivermectin as a therapeutic to fight COVID-19, including data from 7,825 patients across 24 trials. Additionally, according to a meta-analysis recently performed by an independent research consortium, it was calculated that the chances that Ivermectin is ineffective in COVID-19 to be 1 in 67 million.